Carisma Therapeutics' initial CAR-M programs had disappointing results when given systemically (IV), whereas IT delivery is at least showing some early promise https://ashpublications.org/blood/article/146/Supplement%201/4148/555154/Intratumoral-cellular-immunotherapy-with This doesn't doom CAR/TCR-NK platforms, but it does underscore the importance of addressing different barriers, such as trafficking, persistence, and other things going forward.
Market Data 
Markets 
AI
